NCT04666961View on ClinicalTrials.gov

Impact of Neoadjuvant Hormonal Therapy on the Surgical Management of Extensive Ductal Carcinomas in Situ

PHASE2RecruitingINTERVENTIONAL
Enrollment

262

Participants

Timeline

Start Date

February 3, 2021

Primary Completion Date

August 1, 2024

Study Completion Date

August 1, 2033

Conditions
Ductal Carcinoma in SituExtensive DiseaseMastectomy
Interventions
DRUG

Tamoxifen 20 mg

Tamoxifen will be initiated in non menopausal patients orally for 6 months in a neoadjuvant situation.

DRUG

Anastrozole 1Mg Tab

Anastrozole will be initiated in menopausal patients orally for 6 months in a neoadjuvant situation.

Trial Locations (8)

31059

RECRUITING

IUCT-O, Toulouse

33076

RECRUITING

Institut Bergonie, Bordeaux

34298

RECRUITING

Institut de cancérologie de Montpellier, Montpellier

44805

RECRUITING

Institut de Cancérologie de l'Ouest, Saint-Herblain

49055

RECRUITING

ICO - Site Paul Papin, Angers

75005

NOT_YET_RECRUITING

Institut Curie - Site de Paris, Paris

75014

RECRUITING

Hopital Saint Joseph, Paris

06189

RECRUITING

Centre Antoine Lacassagne, Nice

All Listed Sponsors
lead

Institut Cancerologie de l'Ouest

OTHER